Prolonged sulforaphane treatment does not enhance tumorigenesis in oncogenic K-ras and xenograft mouse models of lung cancer

BACKGROUND: Sulforaphane (SFN), an activator of nuclear factor erythroid-2 related factor 2 (Nrf2), is a promising chemopreventive agent which is undergoing clinical trial for several diseases. Studies have indicated that there is gain of Nrf2 function in lung cancer and other solid tumors because o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kombairaju, Ponvijay, Ma, Jinfang, Thimmulappa, Rajesh K, Yan, Shengbin G, Gabrielson, Edward, Singh, Anju, Biswal, Shyam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424666/
https://www.ncbi.nlm.nih.gov/pubmed/22919281
http://dx.doi.org/10.4103/1477-3163.98459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424666/
https://www.ncbi.nlm.nih.gov/pubmed/22919281
http://dx.doi.org/10.4103/1477-3163.98459

Ejemplares similares